RankAlpha logo
Back to Rankings

ACAD

ACADIAC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
8
U.S. public peers
Grade Position
Below peers
vs peer average
ACAD vs peer average
38/100
ACAD vs. peer average (C vs. B)
Grade spread
A 2 · B 2 · C 4
Graded peers loaded
Coverage
8 graded
100% of tracked

Peer overview

CRNX is the first available peer comparator.

Mid-cap biopharma with catalyst-driven valuation sensitivity; useful for reading broader biotech risk appetite, but it is less commercial-stage than ACAD.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerCRNXCrinetics
ACAD
ACADIA
CRNX
Crinetics
Grade
C
C
Momentum
27
10
Value
62
41
Sentiment
75
100
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Mixed
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs CRNX

ACAD / CRNX
Grade Position
Below peers
ACAD vs. peer average (C vs. B)
38/100
Momentum
27
ACAD
Value
62
ACAD
Sentiment
75
CRNX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs ACAD
1
CRNX
CRNX
C
60/100
Even
2
OGN
OGN
A
100/100
-2
3
NAMS
NewAmsterdam Pharma Company NV Common
B
80/100
-1
4
KNSA
Kiniksa Pharmaceuticals International plc Class A Common
C
60/100
Even
5
VKTX
Viking Therapeutics Inc Common
C
60/100
Even
CRNX is the first peer returned for this comparison set.